Quick Answer
REVELATION BIOSCIENCES, INC. reported R&D Expense of $4.06 million for fiscal year 2025.
REVELATION BIOSCIENCES, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.06M | +14.5% |
| 2024 | $3.55M | -14.4% |
| 2023 | $4.15M | -22.9% |
| 2022 | $5.38M | -22.2% |
| 2021 | $6.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $922.9K | +11.1% | -30.0% |
| June 30, 2025 | $1.32M | -5.5% | +53.5% |
| March 31, 2025 | $858.8K | +19.7% | +3.4% |
| September 30, 2024 | $831.0K | -49.7% | -40.4% |
| June 30, 2024 | $1.39M | +53.4% | +94.4% |
| March 31, 2024 | $717.6K | +36.6% | -56.5% |
| September 30, 2023 | $1.65M | +332.8% | +81.6% |
| June 30, 2023 | $909.3K | -6.8% | +73.1% |
- REVELATION BIOSCIENCES, INC. showed an increase of +14.5% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, REVELATION BIOSCIENCES, INC.’s r&d expense has declined by 41.2% (from $6.91 million to $4.06 million).
- The most recent figure is from REVELATION BIOSCIENCES, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: